JAK2 and lymphoma: Finally, the differential expression of mir-373 was reported in several neoplastic diseases except in lymphomas [32]; on the contrary, both the mir-135a downregulation (able to target JAK2) and miR-135a overexpression were associated to relapse of Hodgkin's [33] and follicular and diffuse large B cell lymphomas [29, 31].